Research into psilocybin for end-of-life anxiety has produced some of the most compelling clinical data in psychedelic science. Landmark trials at Johns Hopkins and NYU found that a single guided psilocybin session produced significant, lasting reductions in anxiety,...
Psychedelic therapy contraindications include a personal history of psychosis or mania, current lithium use, certain cardiac conditions, and active suicidal ideation with intent. Some of these are firm stops; others are relative and warrant a careful conversation with...
Ibogaine opioid treatment research has moved significantly forward in 2025 and 2026, with new clinical data, a landmark $50 million Texas state investment, and a federal executive order directing agencies to accelerate review. The evidence shows real potential for...
Last Updated: May 2026 If you’re looking for psychedelic therapy in Washington DC, Maryland, or Virginia (DMV), your clearest option right now is ketamine, which is FDA-cleared and available at licensed clinics across the DMV region. Washington DC has...
Executive burnout psychedelic therapy is moving from the research margins into serious clinical conversation. A growing body of peer-reviewed evidence suggests that psilocybin-assisted therapy can reduce burnout and depressive symptoms more durably than conventional...
Research on psilocybin alcohol use disorder treatment, including a landmark 2022 randomized controlled trial published in JAMA Psychiatry, has shown meaningful reductions in heavy drinking days compared to placebo. The findings are significant, but the research is...
